Why Arrowhead Shot Sky-High, While Ionis Toppled
Arrowhead Pharmaceuticals sees a stock surge following positive Phase 3 trial results for its lipid-lowering drug, causing a decline for competitor Ionis.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Arrowhead Pharmaceuticals reported successful late-stage trial results for Plozasiran, a drug designed to treat severe hypertriglyceridemia. The Phase 3 trials demonstrated that the drug reduces triglycerides and lowers the risk of pancreatitis events.
Coverage from BioPharm International, Fierce Pharma, and Managed Healthcare Executive emphasizes the drug's efficacy in cutting triglycerides. Seeking Alpha and Investor's Business Daily highlight the resulting market shift, noting that Arrowhead's stock rose while Ionis's value dropped.
Future focus remains on the potential impact of these promising hypertriglyceridemia data on the competitive landscape between Arrowhead and Ionis.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What drug produced the positive trial results?
Plozasiran, developed by Arrowhead Pharmaceuticals.
What specific health conditions does the drug address?
Severe hypertriglyceridemia, specifically by reducing triglycerides and pancreatitis risk.
How did the market react to the news?
Arrowhead's stock increased significantly, while Ionis's stock declined.
Coverage (6)
- Why Arrowhead Pharmaceuticals Is Surging 24.4%: JP Morgan Maintains Overweight AlphaStreet · 4h ago
- Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia Managed Healthcare Executive · 5h ago
- Arrowhead's Plozasiran Reduces Triglycerides, Pancreatitis Events in Phase 3 sHTG Trials BioPharm International · 5h ago
- Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug Seeking Alpha · 5h ago
- Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data Fierce Pharma · 5h ago
- Why Arrowhead Shot Sky-High, While Ionis Toppled Investor's Business Daily · 5h ago broke it first
People, places & organizations
Topics
Related trends
AstraZeneca and Ionis Stocks Sink on Trial Miss and Analysts See an Overreaction
4 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.
AstraZeneca, Ionis report major trial failure with heart disease drug
5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.